María Eugenia
Alonso Sarasquete
Investigadora desde 2011
Hospital Universitario Central de Asturias
Oviedo, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Central de Asturias (8)
2020
-
Genomic analysis of a familial myelodysplasia/acute myeloid leukemia and inherited RUNX1 mutations without a pre-existing platelet disorder
Leukemia and Lymphoma
-
Reply to Brown et al: ‘Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis’
Leukemia and Lymphoma
2019
-
Exportin-1 E571K mutation is a common finding in patients with classical Hodgkin lymphoma
Hematological Oncology
2010
-
BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)
Annals of Hematology, Vol. 89, Núm. 5, pp. 453-458
-
Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients
Haematologica, Vol. 95, Núm. 5, pp. 745-751
2009
-
High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics
Leukemia Research, Vol. 33, Núm. 12, pp. 1706-1709
-
Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia
Blood, Vol. 114, Núm. 1, pp. 148-152
2008
-
The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia
Haematologica, Vol. 93, Núm. 12, pp. 1797-1805